JPWO2021076682A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021076682A5 JPWO2021076682A5 JP2022523132A JP2022523132A JPWO2021076682A5 JP WO2021076682 A5 JPWO2021076682 A5 JP WO2021076682A5 JP 2022523132 A JP2022523132 A JP 2022523132A JP 2022523132 A JP2022523132 A JP 2022523132A JP WO2021076682 A5 JPWO2021076682 A5 JP WO2021076682A5
- Authority
- JP
- Japan
- Prior art keywords
- activity
- polypeptide
- sequence
- lbcas12a
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims 53
- 229920001184 polypeptide Polymers 0.000 claims 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims 49
- 102000039446 nucleic acids Human genes 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 27
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 108091034117 Oligonucleotide Proteins 0.000 claims 14
- 102000037865 fusion proteins Human genes 0.000 claims 14
- 108020001507 fusion proteins Proteins 0.000 claims 14
- 101710163270 Nuclease Proteins 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 108020004414 DNA Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 230000035897 transcription Effects 0.000 claims 6
- 238000013518 transcription Methods 0.000 claims 6
- 108060004795 Methyltransferase Proteins 0.000 claims 4
- 230000007022 RNA scission Effects 0.000 claims 4
- 102000008579 Transposases Human genes 0.000 claims 4
- 108010020764 Transposases Proteins 0.000 claims 4
- 101710172430 Uracil-DNA glycosylase inhibitor Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 108020001580 protein domains Proteins 0.000 claims 4
- 229940113491 Glycosylase inhibitor Drugs 0.000 claims 3
- 239000004236 Ponceau SX Substances 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 108700004991 Cas12a Proteins 0.000 claims 2
- 108020001738 DNA Glycosylase Proteins 0.000 claims 2
- 102000028381 DNA glycosylase Human genes 0.000 claims 2
- 230000033616 DNA repair Effects 0.000 claims 2
- 108010046331 Deoxyribodipyrimidine photo-lyase Proteins 0.000 claims 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 2
- 102100034343 Integrase Human genes 0.000 claims 2
- 108010061833 Integrases Proteins 0.000 claims 2
- 241000904817 Lachnospiraceae bacterium Species 0.000 claims 2
- 102000003960 Ligases Human genes 0.000 claims 2
- 108090000364 Ligases Proteins 0.000 claims 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 2
- 102000016397 Methyltransferase Human genes 0.000 claims 2
- 230000010718 Oxidation Activity Effects 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 108091093078 Pyrimidine dimer Proteins 0.000 claims 2
- 102000018120 Recombinases Human genes 0.000 claims 2
- 108010091086 Recombinases Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000029936 alkylation Effects 0.000 claims 2
- 238000005804 alkylation reaction Methods 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000000254 damaging effect Effects 0.000 claims 2
- 230000009615 deamination Effects 0.000 claims 2
- 238000006481 deamination reaction Methods 0.000 claims 2
- 230000027832 depurination Effects 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 239000013635 pyrimidine dimer Substances 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025030119A JP2025087754A (ja) | 2019-10-17 | 2025-02-27 | Ｃａｓ１２ａヌクレアーゼの変異体ならびにその作製方法および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916392P | 2019-10-17 | 2019-10-17 | |
| US62/916,392 | 2019-10-17 | ||
| PCT/US2020/055659 WO2021076682A1 (en) | 2019-10-17 | 2020-10-15 | Variants of cas12a nucleases and methods of making and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025030119A Division JP2025087754A (ja) | 2019-10-17 | 2025-02-27 | Ｃａｓ１２ａヌクレアーゼの変異体ならびにその作製方法および使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022552409A JP2022552409A (ja) | 2022-12-15 |
| JP2022552409A5 JP2022552409A5 (https=) | 2023-10-17 |
| JPWO2021076682A5 true JPWO2021076682A5 (https=) | 2023-10-17 |
| JP7644755B2 JP7644755B2 (ja) | 2025-03-12 |
Family
ID=75492833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523132A Active JP7644755B2 (ja) | 2019-10-17 | 2020-10-15 | Ｃａｓ１２ａヌクレアーゼの変異体ならびにその作製方法および使用方法 |
| JP2025030119A Pending JP2025087754A (ja) | 2019-10-17 | 2025-02-27 | Ｃａｓ１２ａヌクレアーゼの変異体ならびにその作製方法および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025030119A Pending JP2025087754A (ja) | 2019-10-17 | 2025-02-27 | Ｃａｓ１２ａヌクレアーゼの変異体ならびにその作製方法および使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11866745B2 (https=) |
| EP (1) | EP4045643A4 (https=) |
| JP (2) | JP7644755B2 (https=) |
| KR (1) | KR20220097408A (https=) |
| CN (1) | CN114829595A (https=) |
| AU (1) | AU2020366358A1 (https=) |
| BR (1) | BR112022007125A2 (https=) |
| CA (1) | CA3157707A1 (https=) |
| CL (4) | CL2022000937A1 (https=) |
| IL (1) | IL292117A (https=) |
| MX (1) | MX2022004549A (https=) |
| WO (1) | WO2021076682A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| GB201506509D0 (en) | 2015-04-16 | 2015-06-03 | Univ Wageningen | Nuclease-mediated genome editing |
| CN110382692A (zh) * | 2016-04-19 | 2019-10-25 | 博德研究所 | 新型crispr酶以及系统 |
| WO2018022634A1 (en) | 2016-07-26 | 2018-02-01 | The General Hospital Corporation | Variants of crispr from prevotella and francisella 1 (cpf1) |
| WO2022174108A1 (en) * | 2021-02-12 | 2022-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic cas12a for enhanced multiplex gene control and editing |
| CN113136376B (zh) * | 2021-05-26 | 2022-10-21 | 武汉大学 | 一种Cas12a变体及其在基因编辑中的应用 |
| CA3230609A1 (en) * | 2021-09-08 | 2023-03-16 | Shaorong Chong | Compositions comprising a crispr nuclease and uses thereof |
| CN114214348A (zh) * | 2021-11-16 | 2022-03-22 | 河南农业大学 | 应用于核酸检测的Crispr/LbCas12a突变体蛋白及其制备方法和应用 |
| CN118339285A (zh) * | 2021-12-09 | 2024-07-12 | 北京干细胞与再生医学研究院 | 工程化Cas12b效应子蛋白及其使用方法 |
| IL314074A (en) * | 2022-01-06 | 2024-09-01 | Ensoma Aps | CAS12A endonuclease variants and methods of use |
| EP4508205A1 (en) * | 2022-04-12 | 2025-02-19 | John Innes Centre | Compositions and methods for increasing genome editing efficiency |
| AR129505A1 (es) * | 2022-06-01 | 2024-09-04 | Inst Genetics & Developmental Biology Cas | Novedoso sistema de edición de genes crispr |
| CN116286734B (zh) * | 2022-11-29 | 2024-04-02 | 武汉大学 | 野生型LbCas12a蛋白的突变体及SNP检测用途 |
| CN116144631B (zh) * | 2023-01-17 | 2023-09-15 | 华中农业大学 | 耐热型核酸内切酶及其介导的基因编辑系统 |
| WO2024182746A1 (en) | 2023-03-01 | 2024-09-06 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| CN116410955B (zh) * | 2023-03-10 | 2023-12-19 | 华中农业大学 | 两种新型核酸内切酶及其在核酸检测中的应用 |
| CN116179512B (zh) * | 2023-03-16 | 2023-09-15 | 华中农业大学 | 靶标识别范围广的核酸内切酶及其应用 |
| WO2025007140A2 (en) | 2023-06-30 | 2025-01-02 | Christiana Care Gene Editing Institute, Inc. | Nras gene knockout for treatment of cancer |
| KR102789465B1 (ko) | 2023-09-20 | 2025-04-04 | 주식회사 엔세이지 | 신규 CRISPR/Cas12a 시스템 및 그 유전자 편집 용도 |
| CN119432813A (zh) * | 2023-12-29 | 2025-02-14 | 武汉艾迪晶生物科技有限公司 | Cas蛋白、组合蛋白、核酸分子、核糖核蛋白复合物、重组载体、转基因细胞及其应用 |
| CN117844782B (zh) * | 2024-03-06 | 2024-05-31 | 崖州湾国家实验室 | 靶向范围广的基因编辑核酸酶及其在核酸检测中的应用 |
| US20250319206A1 (en) | 2024-04-04 | 2025-10-16 | Christina Care Gene Editing Institute, Inc. | Crispr/cas gene editing of neh4 and/or neh5 domains in nrf2 |
| WO2025226816A1 (en) | 2024-04-23 | 2025-10-30 | Christiana Care Gene Editing Institute, Inc. | Methods of identifying and correlating crispr-induced exon skipping to phenotypic outcomes |
| WO2025244732A1 (en) * | 2024-05-24 | 2025-11-27 | The Regents Of The University Of California | Variant cas12a protein compositions and methods |
| US20260009010A1 (en) | 2024-07-08 | 2026-01-08 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of cas12a |
| US12428636B1 (en) | 2024-07-08 | 2025-09-30 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A |
| CN119506250B (zh) * | 2024-11-29 | 2025-09-09 | 大连理工大学 | 一种多PAM选择的基因编辑系统NovaCas-2及其应用 |
| CN119876148B (zh) * | 2025-01-23 | 2025-10-17 | 中国科学技术大学 | Crispr rna突变体及其在基因编辑和核酸检测中的应用 |
| CN121653102A (zh) * | 2026-02-09 | 2026-03-13 | 武汉艾迪晶生物科技有限公司 | 一种Cas酶突变体及组合蛋白、核酸分子、重组载体、转基因细胞及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| WO2017106657A1 (en) * | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| WO2017127807A1 (en) * | 2016-01-22 | 2017-07-27 | The Broad Institute Inc. | Crystal structure of crispr cpf1 |
| CN110382692A (zh) | 2016-04-19 | 2019-10-25 | 博德研究所 | 新型crispr酶以及系统 |
| CN117925730A (zh) * | 2016-04-21 | 2024-04-26 | 国立大学法人神户大学 | 提高基因组序列修饰技术中的突变导入效率的方法、及其使用的分子复合体 |
| CA3038960A1 (en) * | 2016-09-30 | 2018-04-05 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018195545A2 (en) * | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
| EP3625342B1 (en) | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| WO2018213708A1 (en) | 2017-05-18 | 2018-11-22 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| JP2019016859A (ja) | 2017-07-04 | 2019-01-31 | オリンパス株式会社 | 観察装置および観察方法 |
| CN109957569B (zh) * | 2017-12-22 | 2022-10-25 | 苏州齐禾生科生物科技有限公司 | 基于cpf1蛋白的碱基编辑系统和方法 |
| BR112020014017A2 (pt) | 2018-01-11 | 2020-12-08 | KWS SAAT SE & Co. KGaA | Sistemas crispr / cpf1 de plantas otimizados |
| CN108486146B (zh) * | 2018-03-16 | 2021-02-19 | 中国农业科学院作物科学研究所 | LbCpf1-RR突变体用于CRISPR/Cpf1系统在植物基因编辑中的应用 |
-
2020
- 2020-10-15 BR BR112022007125A patent/BR112022007125A2/pt unknown
- 2020-10-15 JP JP2022523132A patent/JP7644755B2/ja active Active
- 2020-10-15 MX MX2022004549A patent/MX2022004549A/es unknown
- 2020-10-15 CN CN202080087121.8A patent/CN114829595A/zh active Pending
- 2020-10-15 AU AU2020366358A patent/AU2020366358A1/en not_active Abandoned
- 2020-10-15 CA CA3157707A patent/CA3157707A1/en active Pending
- 2020-10-15 US US17/071,095 patent/US11866745B2/en active Active
- 2020-10-15 EP EP20875763.3A patent/EP4045643A4/en active Pending
- 2020-10-15 WO PCT/US2020/055659 patent/WO2021076682A1/en not_active Ceased
- 2020-10-15 KR KR1020227015955A patent/KR20220097408A/ko active Pending
- 2020-10-15 IL IL292117A patent/IL292117A/en unknown
-
2022
- 2022-04-13 CL CL2022000937A patent/CL2022000937A1/es unknown
-
2023
- 2023-11-06 US US18/502,136 patent/US20240076639A1/en active Pending
- 2023-11-06 US US18/502,194 patent/US20240076640A1/en active Pending
-
2024
- 2024-06-11 CL CL2024001734A patent/CL2024001734A1/es unknown
- 2024-06-11 CL CL2024001733A patent/CL2024001733A1/es unknown
- 2024-06-11 CL CL2024001737A patent/CL2024001737A1/es unknown
-
2025
- 2025-02-27 JP JP2025030119A patent/JP2025087754A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021076682A5 (https=) | ||
| US11459588B2 (en) | Methods of use of CRISPR CPF1 hybrid DNA/RNA polynucleotides | |
| JP7788744B2 (ja) | Ｃａｓ９ターゲッティングをガイドする配列に関する方法および組成物 | |
| US11840694B2 (en) | Truncated CRISPR-Cas proteins for DNA targeting | |
| Kowalczykowski | An overview of the molecular mechanisms of recombinational DNA repair | |
| KR102254602B1 (ko) | Cas9 변이체 및 그의 용도 | |
| EP2828386B1 (en) | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX | |
| US20190300867A1 (en) | Bypassing the pam requirement of the crispr-cas system | |
| US20150166982A1 (en) | Methods for correcting pi3k point mutations | |
| US20030148275A1 (en) | Nuclease | |
| CN110139927A (zh) | Crispr-cas9抑制剂 | |
| CN102124112A (zh) | 基于同源重组dna的克隆方法及组合物 | |
| CA3097044A1 (en) | Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents | |
| US20220243213A1 (en) | Anti-crispr inhibitors | |
| JP2022551931A (ja) | 改変エンドヌクレアーゼおよび関連方法 | |
| US20240301445A1 (en) | Crispr-associated transposon systems and methods of using same | |
| JP2024509047A (ja) | Ｃｒｉｓｐｒ関連トランスポゾンシステム及びその使用方法 | |
| US20250243511A1 (en) | Crispr-associated transposon systems and methods of using same | |
| US20080254516A1 (en) | Method of Isolating Nucleic Acid Targets | |
| CN120092083A (zh) | 包含Cas蛋白和细菌毒素的融合蛋白及其用途 | |
| JPWO2023139557A5 (https=) | ||
| JP4681129B2 (ja) | 核酸末端領域の非対称的修飾法 | |
| EP4504918A1 (en) | Continuous multiplexed phage genome engineering using a retron editing template | |
| WO2026086827A1 (zh) | 乳杆菌源TnpB编辑系统及其应用 | |
| Affinity | Transcriptional Repressor CopR: Use of |